News Relief for AZ as Truqap hits the spot in prostate cancer After a disappointing result with Truqap in triple-negative breast cancer, AstraZeneca chalks up a win in prostate cancer
News Roche finally drops curtain on AKT drug ipatasertib In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.
